Provenance Record

Well-structured Analysis piece (739 words, within the 800-2000 range allowance for the format) with clear Overview / What We Know / Background / Analysis / What We Don't Know sections. Technical depth is appropriate; the framing (a licensing model in pharma, Sanofi both investor and customer) is supported by the cited material and does not editorialize.

All 5 source snapshots read from disk (all HTTP 200, no archive fallback, no bot-blocks). source-0 (Owkin newsroom): confirms the five-year K Pro license, the 'biopharma agents' framing, the 'work like intelligent assistants, autonomously performing complex tasks in drug research and development' quote (verbatim), the K Pro 'combines multimodal patient data...from early discovery through clinical development' description (verbatim), the Clozel quote (verbatim, correct speaker: CEO and Co-founder of Owkin), the Frenehard quote (verbatim, correct speaker: Chief Digital Officer at Sanofi), and the 2021 €90M oncology/immunology history. source-1 (CDO Magazine): confirms the five-year license and 2021 €90M oncology target ID + patient stratification later broadening to immunology. source-2 (mHealthSpot): confirms multimodal patient data combining genetic information, medical imaging, clinical records (verbatim support for the claim cited to mHealthSpot). source-3 (Wikipedia, allowlisted): confirms ALL load-bearing founding/funding specifics verbatim — founded 2016 in Paris by Clozel and Wainrib (professor of AI), 'raised over $255 million and became a unicorn... in November 2021 through a $180 million investment from... Sanofi', and K Pro 'draws on 26.5 million scientific articles, 19 biomedical databases, and multiomic data from Owkin's MOSAIC... first released in May 2025'. source-4 (IT Digest): confirms the comparison AstraZeneca three-year K Pro deal, agents running inside AstraZeneca's IT infrastructure for competitive-intelligence questions reducing manual analysis, the Clozel 'future of the pharmaceutical industry is agentic' quote (verbatim, correct speaker), and the article's 'May 2026' dating (IT Digest piece dated May 13, 2026).

Every quote is verbatim and correctly attributed. Every specific (five-year term, €90M, $180M, $255M, November 2021, 2016 Paris founding, 26.5M articles/19 databases/MOSAIC/May 2025, AstraZeneca three-year deal) traces to a cited source. Announcement-date discrepancy handled responsibly: Owkin's release is dated June 5, 2026 while CDO and mHealthSpot date the story June 10, 2026 — the article correctly hedges to 'in early June' rather than asserting one exact date. No hallucinations detected.

Substantively accurate, neutral, original Analysis with every quote and specific verified against its cited snapshot. The only issue is that four sources sit off the allowlist — a sourcing-transparency matter, not a factual one — which the corrections mechanism can honestly disclose. Approving with corrections.